Abstract: This invention involves immunizing mice with human ecto-5?-nucleotidase (CD73) to obtain multiple monoclonal antibodies whose heavy-chain and light-chain sequences are both novel amino acid sequences and which can be used to prepare CD73 enzyme activity inhibitors and anti-tumor drugs.

Abstract: This invention provides a protein that is highly effective in lowering blood glucose. Experimental results have shown that the protein can be used to prepare a drug for treating diabetes.

Abstract: This invention provides a novel protein. Experimental results have shown that the protein has agonist activity at three receptors, namely the glucagon-like peptide 1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon (Gcg) receptor, and has both blood glucose lowering and body weight reducing functions.

Abstract: A modified recombinant human nerve growth factor (modified rhNGF) is obtained from the reaction between a polymer of formula A and an rhNGF. The polymer of formula A is an N-disubstituted amino acetamino aldehyde derivative. Experimental results have shown that the modified rhNGF has a higher in vivo plasma concentration and a longer in vivo half-life than when the rhNGF is not modified or is modified by monomethoxy polyglycol, and that the modified rhNGF preserves the original activity of the unmodified rhNGF. Moreover, the method of preparing the modified rhNGF is low-cost, and the modified products are highly consistent.

Abstract: A long-acting preparation made from a protein having the amino acid sequence of SEQ ID NO. 1 or SEQ ID NO. 2 or from a modified protein of the protein for improving sexual dysfunction. The modified protein is the protein molecule connected with another protein or with another chemical substance.